Goutham Sunny
@medoncodoc
Followers
1K
Following
7K
Media
416
Statuses
4K
Asst Prof, Medical Oncology @GCRI_1972 @offcmcvellore alumni #pantumor 🧬🌐, Academic account, #medtwitter. Follow @gsrocks007 for personal account.
India
Joined December 2009
DLBCL treatment has gotten more complicated Back in my day it was RCHOP if relapse salvage and ASCT
5
57
226
Rechallenge benefit score New data from a 16-center French study shows that routine inflammation-based biomarkers can help identify which NSCLC patients may benefit from ICI rechallenge. The Rechallenge Benefit Score (RBS) outperforms clinical features, stratifies rPFS
0
0
0
Phase 2 KANNON shows that andamertinib 240 mg daily delivers meaningful activity in previously treated EGFR exon20 insertion–mutant NSCLC. ORR 42.7%, disease control 86.5%, median DOR 8.7 months, and encouraging CNS activity with ORR 47.4% in patients with brain metastases.
0
0
1
🐘 The elephant in the room: we don’t know how to sequence all these TOPO1 ADCs.
#ESMO25 ADCs in chemo-pretreated HR+/HER2− mBC: Phase 3 studies From Dr. Javier Cortés' great discussion on ADCs👇
2
25
108
Options for HER2-positive breast cancer are increasing🚀🎉 It was announced that maintenance tucatinib combined with HP after THP provides a significant PFS advantage (HER2CLIMB-05) Now we have 3 new options. Minds are confused. Data mining awaits us🤯
3
45
140
INTERLACE or KEYNOTE-A18 for #CervicalCancer ? 🤔 It’s all about patient selection, risk profile, safety and clinical context💡 @OncoAlert
3
45
107
So proud of @jtgeorgy and the whole team at @OffCMCVellore for doing such an impactful and relevant study for India and all LMICs. Truly amazing work 🫡
🚨Out in @SciReports @NaturePortfolio our study from @OffCMCVellore @todrashish Low-dose nivolumab + induction chemo in unresectable/loc advanced HNSCC led to 75 % ORR, 31 % conversion to resectability, ~90 % cost reduction. See below 🧵on our findings👇 https://t.co/E8IfVeDjNI
0
0
4
Happy to share our experience... What immunotherapy can achieve in advanced non metastatic HNSCC ? hope this will help our patients in india.. 🇮🇳 @ICMRDELHI
@csoncol
nature.com
Scientific Reports - Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive...
9
16
47
A quick reckoner on comparison of 1st line TKIs for ALK+ NSCLC. Which one do you use in 1L? Where does brigatinib fit in, with Alectinib being available for lesser cost and Lorlatinib having crazy efficacy? @SuyogCancer @OncBrothers @StephenVLiu @medoncodoc @dr_yakupergun
2
6
22
Bloomberg @business (Global, NY) @RobertLangreth recently featured our work from @OffCMCVellore Medical Oncology & Haematology and @TataMemorial: low-dose immunotherapy and potential for equitable cancer care. What if 1/6th the dose works just as well? https://t.co/CYAuvUz609
3
19
32
I was away from X for ~3 months due to personal work and now have ~2000 publications to catch up on. In oncology, if you don’t stay updated, you risk becoming outdated fast. The pace at which knowledge evolves—and irrelevance sets in—is truly brutal #studentforlife
1
1
5
Dear All, We are delighted to invite you to the Inaugural Webinar of the Common Sense Oncology (CSO) India Hub scheduled for Wednesday, September 17, 2025, from 07:00 PM to 08:00 PM (IST). This session will discuss principles of CSO followed by critical appraisal of MATTERHORN
1
1
1
CSO India hub’s inaugural webinar is happening today where we discuss the Matterhorn trial in detail. Please do consider joining us. Details in comments.
2
5
14
Nice slide for cross trial comparison Flaura , Flaura 2 amd Marriposa. by Dr Daniel Tan #WCLC2025 . Don't miss the last row .
0
61
164
In our recent post, we provided trial names for AI models to rank as the most anticipated plenary data at WCLC 2025. This time, we asked AI models to independently identify the top 10 most anticipated interventional trials in thoracic oncology expected at @IASLC – WCLC 2025.
0
13
28
For now… cross trial comparison is all we have! This will come over and over in our clinics for Her2+ non-small cell lung cancer. Sequencing and AE discussions so that our pts can make informed/shared decision (@jillfeldman4 🙏🏽🙏🏽) ! #Zongertinib #TDxD #lcsm #OncTwitter
Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ @JSabari Full 🗣️: ⭐️ https://t.co/Y5WjnOlts8 ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm @OncUpdates
3
16
73
Infections in cancer. Addressed 10 key issues. @TataMemorial @ACTREC_TMC @VanitaNoronha @SuyogCancer @Amolpatel_dr @DrNikitaMehra @cspramesh @IJMPOofficial @bagalbp @SirohiBhawna @ajumathew_
https://t.co/EzLI4jFtC5
ecancer.org
Expert insights: 10 key questions on managing common infections in cancer care in India Lingaraj Nayak1,2, Gaurav Salunke2,3, Trupti Gilada4, Sukhada Savar
2
14
30
Congratulations @jtgeorgy and the whole team involved @OffCMCVellore
📢Our new paper @OffCMCVellore Pathology, MedOnc out in @ecancer
https://t.co/Tv8wcQScOh After Dr. @ullas_batra's report, this is largest Indian series of tepotinib-Rxed METex14 mNSCLC. Led by @todrashish, Dr. Rekha Pai @ajoel_84, Dr. Rohini @ajoyojohn Dr. Deepa Susan #LCSM
0
1
8
Hepatic metastases management: A comparative review of surgical resection, thermal ablation, and stereotactic body radiation therapy Eur J Cancer https://t.co/K5Sk7W7BSE 🔎narrative review 👉multiple complementary options 👉Surgery most effective, but RFA & SBRT valid
4
42
141
🚨 Potential Practice Changer in #BladderCancer 🚨 KEYNOTE-905 (EV-303) – cisplatin-ineligible MIBC Peri-op pembrolizumab + enfortumab vedotin vs surgery alone: ✅ ↑ Event-Free Survival ✅ ↑ Overall Survival ✅ ↑ Pathologic CR rates 📌 First Phase 3 to show survival benefit
3
29
101